News Lilly grabs first-ever FDA nod for a sleep apnoea drug Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.
Digital How measurement technology can advance sleep monitoring in c... As of 2024, more than one-third of American adults don't get enough sleep, and sleep satisfaction levels are worryingly low.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.